• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

200 mg/m(2) melphalan--the gold standard for multiple myeloma.

作者信息

Giralt Sergio

出版信息

Nat Rev Clin Oncol. 2010 Sep;7(9):490-1. doi: 10.1038/nrclinonc.2010.104.

DOI:10.1038/nrclinonc.2010.104
PMID:20798699
Abstract
摘要

相似文献

1
200 mg/m(2) melphalan--the gold standard for multiple myeloma.200毫克/平方米美法仑——多发性骨髓瘤的金标准。
Nat Rev Clin Oncol. 2010 Sep;7(9):490-1. doi: 10.1038/nrclinonc.2010.104.
2
Is the low-thalidomide dose MPT regimen beneficial?低剂量沙利度胺的MPT方案是否有益？
Korean J Intern Med. 2011 Dec;26(4):400-2. doi: 10.3904/kjim.2011.26.4.400. Epub 2011 Nov 28.
3
Triple MEL100 therapy in multiple myeloma.多发性骨髓瘤的三联MEL100疗法。
Transplant Proc. 2009 Nov;41(9):3863-7. doi: 10.1016/j.transproceed.2009.06.196.
4
Melphalan hydrochloride for the treatment of multiple myeloma.用于治疗多发性骨髓瘤的盐酸美法仑。
Expert Opin Pharmacother. 2017 Aug;18(11):1127-1136. doi: 10.1080/14656566.2017.1349102. Epub 2017 Jul 10.
5
Further progress in the treatment of multiple myeloma?多发性骨髓瘤治疗的进一步进展？
Natl Med J India. 2009 Jan-Feb;22(1):25-7.
6
Melflufen: A Next-Generation Nitrogen Mustard.
J Clin Oncol. 2021 Mar 1;39(7):836-839. doi: 10.1200/JCO.20.03326. Epub 2021 Jan 13.
7
Melphalan and its role in the management of patients with multiple myeloma.美法仑及其在多发性骨髓瘤患者治疗中的作用。
Expert Rev Anticancer Ther. 2007 Jul;7(7):945-57. doi: 10.1586/14737140.7.7.945.
8
Treatment of multiple myeloma in patients with Gaucher disease.戈谢病患者多发性骨髓瘤的治疗
Am J Hematol. 2009 Oct;84(10):694-6. doi: 10.1002/ajh.21492.
9
In focus: (166) Ho-DOTMP in the pretransplant treatment of multiple myeloma.
Clin Adv Hematol Oncol. 2004 Nov;2(11):753-4.
10
Treatment of myeloma: recent developments.骨髓瘤的治疗：最新进展
Anticancer Drugs. 2002 Apr;13(4):339-51. doi: 10.1097/00001813-200204000-00002.

引用本文的文献

1
Outcomes of melphalan 140 mg/m followed by autologous stem cell transplantation in multiple myeloma patients with co-morbidities: Single-centre experience.患有合并症的多发性骨髓瘤患者接受140毫克/平方米美法仑治疗后进行自体干细胞移植的结果：单中心经验
EJHaem. 2024 Aug 19;5(5):1102-1106. doi: 10.1002/jha2.977. eCollection 2024 Oct.
2
The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma.泊马度胺联合来那度胺治疗多发性骨髓瘤的临床观察。
Int J Mol Sci. 2022 Dec 10;23(24):15671. doi: 10.3390/ijms232415671.
3
Melphalan 140 mg/m or 200 mg/m for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.

本文引用的文献

1
Importance of achieving a complete response in multiple myeloma, and the impact of novel agents.多发性骨髓瘤中实现完全缓解的重要性，以及新型药物的影响。
J Clin Oncol. 2010 May 20;28(15):2612-24. doi: 10.1200/JCO.2009.25.4250. Epub 2010 Apr 12.
2
The role of maintenance therapy in the treatment of multiple myeloma.维持治疗在多发性骨髓瘤治疗中的作用。
J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S21-7. doi: 10.6004/jnccn.2010.0113.
3
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.
马法兰 140 毫克/平方米或 200 毫克/平方米用于骨髓瘤的自体移植：来自收集淋巴瘤和骨髓瘤自体移植结果的协作组（CALM）研究的结果。EBMT 慢性恶性肿瘤工作组的报告。
Haematologica. 2018 Mar;103(3):514-521. doi: 10.3324/haematol.2017.181339. Epub 2017 Dec 7.
4
DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.骨髓瘤浆细胞的DNA修复与临床结局相关：非同源末端连接抑制剂SCR7的作用。
Blood. 2016 Sep 1;128(9):1214-25. doi: 10.1182/blood-2016-01-691618. Epub 2016 Jul 21.
5
Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.意大利多发性骨髓瘤门诊自体干细胞移植管理共识会议
Bone Marrow Transplant. 2016 Aug;51(8):1032-40. doi: 10.1038/bmt.2016.79. Epub 2016 Apr 4.
6
Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.染色质结构、转录活性和DNA修复效率影响多发性骨髓瘤化疗的结果。
Br J Cancer. 2014 Sep 23;111(7):1293-304. doi: 10.1038/bjc.2014.410. Epub 2014 Jul 22.
7
First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.一线串联大剂量化疗及自体干细胞移植与单一大剂量化疗及自体干细胞移植治疗多发性骨髓瘤的对照研究系统评价
Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD004626. doi: 10.1002/14651858.CD004626.pub3.
马法兰 200mg/m(2)与马法兰 100mg/m(2)治疗初诊多发性骨髓瘤患者的前瞻性、多中心 3 期研究。
Blood. 2010 Mar 11;115(10):1873-9. doi: 10.1182/blood-2009-09-241737. Epub 2009 Dec 1.
4
Symptom burden in patients undergoing autologous stem-cell transplantation.接受自体干细胞移植患者的症状负担
Bone Marrow Transplant. 2007 Jun;39(12):759-66. doi: 10.1038/sj.bmt.1705664. Epub 2007 Apr 16.
5
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol.高危初发多发性骨髓瘤的序贯自体干细胞移植：前瞻性随机IFM 99 - 04方案的最终结果
Blood. 2006 Jan 1;107(1):397-403. doi: 10.1182/blood-2005-06-2573. Epub 2005 Sep 6.
6
Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study.氨磷汀与递增剂量美法仑的自体造血干细胞支持：一项I期研究。
Biol Blood Marrow Transplant. 2004 Jul;10(7):473-83. doi: 10.1016/j.bbmt.2004.03.001.
7
Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma.
J Clin Oncol. 2002 Mar 1;20(5):1319-28. doi: 10.1200/JCO.2002.20.5.1319.
8
Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.200mg/m²美法仑与8Gy全身照射加140mg/m²美法仑作为新诊断多发性骨髓瘤患者外周血干细胞移植预处理方案的比较：法语国家骨髓瘤研究组9502随机试验的最终分析
Blood. 2002 Feb 1;99(3):731-5. doi: 10.1182/blood.v99.3.731.